|
Laxman Pai, Opalesque Asia: New B2B life science investor Biospring Partners announced the closing of its debut fund with north of $245 million in capital commitments from pension plans, fund of funds, endowments and foundations, and family offices.
According to a press release from the growth equity firm, it aims to invest in companies with the potential to fundamentally shift how technology is utilized across the life sciences sector.
Co-Founders and Managing Partners, Michelle Dipp, M.D., Ph.D., and Jennifer Lum, believe that life sciences innovation is accelerating due to increasing access to sequencing, cloud computing, and machine learning technologies in addition to significant advancements in synthetic biology and gene editing, it said.
"Biospring's investments are working to push the healthcare industry forward by enabling new forms of biopharma manufacturing, diagnostic testing, and software applications that are fundamentally changing how we research, diagnose, and treat disease," the release said.
"We focus on identifying long-term themes within life sciences technology to identify biopharma services, tools, and software companies at the growth stage. We aim to partner with management teams before investing in them to add value through our experience and network," Michelle Dipp said.
A physician-scientist by training, Dipp has invested as a General Partner for over 12 years. Before Biospring, Michelle Dipp was a Managing Director at Ge...................... To view our full article Click here
|
RSS
